Online citations, reference lists, and bibliographies.

Sickle Cell Disease Related Mortality In The United States (1999-2009).

Dima Hamideh, O. Álvarez
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Little is known about the national outcome of children and adults with sickle cell disease (SCD) given contemporary care. PROCEDURE We investigated the number of deaths, standardized crude and age-adjusted mortality rates, and causes of death among individuals with SCD across the United States during 1999-2009 according to death certificates by using a publicly available website (http://wonder.cdc.gov/). Data were compared to mortality during 1979-1998. RESULTS When compared to 1979-1998, mortality significantly decreased by 61% in infants <1 year of age, by 67% in children aged 1-4 years, and by 22-35% in children aged 5-19 years. After 19 years of age, mortality rates increased from 0.6 in the 15-19 year group to 1.4/100,000 in the 20-24 year group, corresponding to the transition period from pediatric to adult medical care, and this increase was similar during 1979-1998. Although the age groups with the highest mortality were 35-44 years for males and 45-54 years for females, there was a tendency for longer survival because there were more deaths among those individuals 55-74 years of age compared to previous years. For all individuals, the causes of deaths were cardiac disease (31.6%), respiratory (28.1%), renal (16.4%), infectious (14.4%), neurologic (11.9%), and gastrointestinal and hepatobiliary (9.2%) in nature. Cancer was the cause of death in <1%. CONCLUSION Mortality during childhood has decreased significantly. However, the transition period from pediatric to adult care is critical. Risk-reduction, monitoring, and early treatment intervention of cardiovascular disease in adults is warranted.
This paper references
10.1016/S0022-3476(85)80284-5
Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age.
M. Lepow (1985)
10.1542/peds.2007-0018
Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease in the First Decade of Life
T. Adamkiewicz (2008)
10.1056/NEJM199807023390102
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.
R. Adams (1998)
10.1067/S0022-3476(03)00331-7
Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.
T. Adamkiewicz (2003)
10.1182/BLOOD.V116.21.843.843
Hydroxyurea Therapy Reduces Mortality Among Children with Sickle Cell Disease
Clarisse Lobo (2010)
10.1002/ajh.21569
Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease
C. Fitzhugh (2010)
10.1111/j.1365-2141.2006.06417.x
Severity of pulmonary hypertension during vaso‐occlusive pain crisis and exercise in patients with sickle cell disease
Roberto F. Machado (2007)
10.1182/blood-2009-07-233700
Improved survival of children and adolescents with sickle cell disease.
C. Quinn (2010)
10.1182/blood-2009-04-218040
Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.
V. Gordeuk (2009)
10.1056/NEJM199406093302303
Mortality in sickle cell disease. Life expectancy and risk factors for early death.
O. Platt (1994)
Deaths: preliminary data for 2011.
D. Hoyert (2012)
10.1182/BLOOD-2005-10-009506
Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results.
M. Lee (2006)
10.1097/01.inf.0000133046.60555.de
Elimination of Racial Differences in Invasive Pneumococcal Disease in Young Children After Introduction of the Conjugate Pneumococcal Vaccine
T. R. Talbot (2004)
10.1056/NEJM200006223422502
Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
P. V. Ichinsky (2000)
10.1056/NEJM198606193142501
Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial.
M. H. Gastón (1986)
Newborn screening for sickle cell disease.
T. Gross (1989)
10.1542/PEDS.106.2.362
Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis
J. Abramson (2000)
10.1002/ajh.21699
The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up
M. Steinberg (2010)
An expanded pneumococcal vaccine (prevnar 13) for infants and children.
(2010)
10.1086/516781
Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.
N. Halasa (2007)
10.1164/rccm.200710-1606OC
Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease.
A. Mekontso Dessap (2008)
10.1136/adc.2003.027326
Myocardial ischaemia in children with sickle cell disease
M. de Montalembert (2004)
10.1016/j.amepre.2009.12.022
Population estimates of sickle cell disease in the U.S.
K. Hassell (2010)
10.1182/blood.V86.2.776.bloodjournal862776
Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.
F. Gill (1995)
10.1002/pbc.24100
Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.
O. Alvarez (2012)
10.1542/peds.2010-1280
Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)
J. Bocchini (2010)
10.1136/bmj.285.6342.633
Causes of death in sickle-cell disease in Jamaica.
A. Thomas (1982)
Newborn screening for sickle cell disease: effect on mortality.
E. Vichinsky (1988)
Mortality. In: Statistical notes for health
JC Kleinman (1977)
10.1016/j.amepre.2010.01.005
The registry and surveillance in hemoglobinopathies: improving the lives of individuals with hemoglobinopathies.
William Keith Hoots (2010)
Newborn screening coupled with comprehensive follow-up reduced early mortality of sickle cell disease in Connecticut.
Tamiesha Frempong (2007)
10.1016/J.YPED.2011.09.024
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
J. Stockman (2013)
10.1056/nejm200009143431122
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.
E. Vichinsky (2000)
10.1067/MPD.2000.109437
US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN).
K. Pass (2000)
10.1111/j.1365-2141.2010.08271.x
Outcome of adults with sickle cell disease admitted to critical care – experience of a single institution in the UK
K. Gardner (2010)
Preventing pneumococcal disease among infants and young children : recommendations of the Advisory Committee on Immunization Practices (ACIP)
Orin S. Levine (2000)
10.1182/blood-2012-04-383430
Sickle cell pain: a critical reappraisal.
S. Ballas (2012)
10.1001/archpedi.1990.02150280088018
Newborn screening for hemoglobinopathies in Colorado. The first 10 years.
J. Githens (1990)
10.1542/PEDS.109.3.526
Health supervision for children with sickle cell disease.
Section on Hematology (2002)
10.1182/BLOOD-2003-11-3758
Survival of children with sickle cell disease.
C. Quinn (2004)



This paper is referenced by
10.1038/bmt.2015.65
Sickle cell disease is not so benign
M. Hsieh (2015)
Evaluation of a community-based organization’s transition program for sickle cell disease and its effect on adolescents’ and young adults’ transition readiness
E. Mazzei (2018)
10.1016/j.bjhh.2014.11.001
The invisibility of sickle cell disease in Brazil: lessons from a study in Maranhão☆
Marcos Borato Viana (2015)
10.1080/09297049.2015.1111318
Association of social-environmental factors with cognitive function in children with sickle cell disease
Janet Yarboi (2017)
10.1590/2177-9465-ean-2019-0194
Fatores de risco para mortalidade em pacientes com doença falciforme: uma revisão integrativa
Carolina Mariano Pompeo (2020)
10.1007/174_2014_965
Thoracic Manifestations of Systemic Diseases
David Holland (2014)
10.1515/ijamh-2015-0010
Development of a sickle cell disease readiness for transition assessment
Marsha Treadwell (2016)
10.1007/978-3-319-43827-6_16
Sickle Cell Disease
Kathryn L Hassell (2016)
10.1001/jamanetworkopen.2019.15374
Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease.
D. Lubeck (2019)
10.1111/trf.14575
Automated RBC exchange compared to manual exchange transfusion for children with sickle cell disease is cost‐effective and reduces iron overload
L. Dedeken (2018)
Lymphoid Hematopoiesis and the Role of B-cells in Transgenic Mouse Model of Sickle Cell Disease
Christina Cotte (2017)
10.1007/s12325-015-0197-1
A Biopsychosocial Model for the Management of Patients With Sickle-Cell Disease Transitioning to Adult Medical Care
Lori E Crosby (2015)
10.5772/INTECHOPEN.84601
Introductory Chapter: Contemporary Pediatric Hematology and Oncology
Marwa M Zakaria (2019)
10.1097/PCC.0000000000001468
Early Noninvasive Ventilation and Nonroutine Transfusion for Acute Chest Syndrome in Sickle Cell Disease in Children: A Descriptive Study
C. Heilbronner (2018)
10.1016/j.exphem.2018.05.004
Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
K. Sii-Felice (2018)
children with ''less severe'' sickle cell disease The ethics of a proposed study of hematopoietic stem cell transplant for
R. Nickel (2014)
10.1016/j.pathol.2016.10.002
Sickle cell disease in the older adult.
M. S. Thein (2017)
Neurological Manifestations of Hemoglobinopathies
Sophia Delicou (2017)
Genetic Dissection and In Vivo Modeling of Sickle Cell Disease Nephropathy
Blair R. Anderson (2016)
10.1182/bloodadvances.2019001378
Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.
Omar Niss (2020)
10.1002/ajh.24498
Patterns of opioid use in sickle cell disease
J. Han (2016)
10.1002/pbc.26322
National registry of hemoglobinopathies in Spain (REPHem)
E. Cela (2017)
10.1097/01.med.0000436192.25846.0b
An update on the recent literature on sickle cell bone disease
I. Osunkwo (2013)
10.1016/j.atg.2016.03.005
Proceedings of a Sickle Cell Disease Ontology workshop — Towards the first comprehensive ontology for Sickle Cell Disease
Nicola J. Mulder (2016)
10.1007/978-3-319-26033-4_3
Enhancing Coping and Resilience Among Families of Individuals with Sickle Cell Disease
S. Mayes (2017)
10.1080/17474086.2018.1486703
Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced
Alexis Leonard (2018)
10.1177/1062860617707262
A Multidisciplinary Approach to Impact Acute Care Utilization in Sickle Cell Disease
Rhea E Powell (2018)
10.3390/jcm8111796
Is There Any Improvement of the Coagulation Imbalance in Sickle Cell Disease after Hematopoietic Stem Cell Transplantation?
Laurence Rozen (2019)
10.1016/j.bbmt.2017.08.034
Ethical Challenges in Hematopoietic Cell Transplantation for Sickle Cell Disease.
R. Nickel (2018)
10.1097/MPH.0000000000000427
Transitioning Adolescents and Young Adults With Sickle Cell Disease From Pediatric to Adult Health Care: Provider Perspectives
Natalie B Stollon (2015)
10.1002/pbc.27722
Implementation of an educational intervention to optimize self-management and transition readiness in young adults with sickle cell disease.
Cecelia L Calhoun (2019)
10.1002/pbc.25446
Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia.
E. Meier (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar